We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Agreement to License UltiMAb Human Antibody Development System®
News

Agreement to License UltiMAb Human Antibody Development System®

Agreement to License UltiMAb Human Antibody Development System®
News

Agreement to License UltiMAb Human Antibody Development System®

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Agreement to License UltiMAb Human Antibody Development System® "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Medarex, Inc. has announced an agreement to license the use of Medarex's UltiMAb Human Antibody Development System® to ImClone Systems Incorporated.

ImClone Systems has informed Medarex that ImClone Systems intends to use the UltiMAb® system to develop human antibody product candidates against its disease targets, which are primarily in the area of oncology.

Under the terms of the agreement, Medarex will receive license fees as well as milestone payments relating to the development of any products that result from ImClone Systems' use of the UltiMAb system and royalties on commercial sales of products resulting from this agreement.

"We are pleased that ImClone Systems plans to combine our UltiMAb technology with their experience in the development of antibody therapeutics," said Donald L. Drakeman, President and CEO of Medarex, Inc.

Advertisement